Possible biomarker to gauge Alzheimer’s prognosis identifiedMarch 18th, 2011 - 4:39 pm ICT by ANI
Washington, Mar 18 (ANI): Scientists have discovered a new biomarker that could help them track how effectively the immune system is able to clear the brain of amyloid beta, which forms the laques considered one of the hallmarks of Alzheimer’s disease.
The pilot study, conducted by UCLA researchers, demonstrates how the immune gene MGAT3, which is essential in clearing amyloid beta, is expressed differently in different Alzheimer’s patients.
The finding may be useful in providing more highly individualized disease prognosis in the future. It may also help researchers understand which patients will respond to therapy with vitamin D3 and curcumin, a chemical found in turmeric spice, both of which were shown in previous studies by this UCLA research team to help stimulate specific immune system cells to clear amyloid beta in a laboratory test.
In earlier research, the team showed that Alzheimer’s patients may have a defect in messaging from the MGAT3 gene, which could help explain why this population cannot effectively clear amyloid beta.
In the current study, researchers used a blood-based biomarker to identify three abnormal ways of processing MGAT3 gene information, which could lead to different disease prognosis.
“Alzheimer’s disease robs a person of identity and is a huge burden for families, caregivers and society,” said study author Dr. Milan Fiala, a researcher at the David Geffen School of Medicine at UCLA and the Veterans Affairs Greater Los Angeles Healthcare System. “This is one of the first studies demonstrating the role of the immune system in helping track Alzheimer’s disease prognosis and the impact of therapies.”
For the study, scientists drew blood samples from 20 Alzheimer’s disease patients and 20 healthy controls and then isolated critical immune cells from the blood called macrophages, which are responsible for gobbling up amyloid beta and other waste products in the brain and body.
They incubated the immune cells overnight with amyloid beta to test the cells’ ability to “turn on” MGAT3. They also added a synthetic form of curcumin to some of the cells to gauge the effect it had on MGAT3 expression and the absorption of amyloid beta.
Based on the results, the researchers identified three groups of Alzheimer’s patients.
Type 0 patients: This group had very low expression of MGAT3 and very low absorption rates of amyloid beta.
Type I patients: This group also had low expression of MGAT3 and low amyloid beta absorption rates, but the strength of the MGAT3 message and the absorption of amyloid beta increased when researchers stimulated the macrophages with synthetic curcumin.
Type II patients: This group initially had high amyloid beta absorption rates, but when scientists added synthetic curcumin, MGAT3 expression lessened and absorption was reduced.
In addition, researchers found that for Type I and Type II patients, the clearing of amyloid beta was dependent on vitamin D3, a type of vitamin D that occurs naturally in these cells. When they blocked vitamin D3 use by the macrophages in the laboratory, they found that absorption of amyloid beta suffered.
“These findings demonstrate three very different levels of immunity and possible reactions to natural therapies of vitamin D3 and curcumin,” Fiala said. “These differences could point to a new way to track the progression of Alzheimer’s disease and the effectiveness of these natural therapies based on an individual patient’s immunity.”
The study has been published online in the Journal of Alzheimer’s Disease. (ANI)
- Potent new vaccine found effective against Alzheimer's - Jun 08, 2012
- Drug reverses Alzheimer's symptoms in mice: Study - Feb 10, 2012
- Turmeric-based drug being tested against Alzheimer's - Feb 15, 2012
- Insulin could play powerful role in fighting Alzheimer's - Apr 02, 2011
- Liver, not brain, may be source of Alzheimer's plaques - Mar 04, 2011
- 'Vitamin C keeps dementia at bay' - Sep 12, 2012
- Simple blood test may predict Alzheimer's risk - Jul 14, 2009
- Insulin found promising in treating Alzheimer's - Apr 03, 2011
- Novel gene therapy shows promise against Alzheimer's - Mar 05, 2011
- Drug reversing Alzheimer's symptoms found - Feb 12, 2012
- Scientists eliminate plaque formation in Alzheimer's - Sep 06, 2012
- Drug boosts body's receptivity to Vitamin D - Jul 31, 2012
- Indications of Alzheimer's may be evident decades before first signs - Mar 29, 2011
- Ray of sunshine boon for critically ill - Apr 04, 2012
- Second molecule in Alzheimer's toxic duo identified - Feb 04, 2011
Tags: biomarker, blood samples, brain and body, david geffen school, david geffen school of medicine, david geffen school of medicine at ucla, disease patients, disease prognosis, earlier research, fiala, immune cells, immune system cells, laboratory test, macrophages, pilot study, study author, study researchers, ucla research, ucla researchers, vitamin d3